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Abstract
Atherosclerotic plaques can form in the blood vessels from particles of
cholesterol. These plaques are a major cause of cardiovascular disease and
have the ability to result in fatal cardiovascular events. In researching this
topic, PubMed, the Cochrane Library, DynaMed, and ClinicalKey were all
utilized in finding articles published from 2002 to 2018. There are several
organizations with conflicting guidelines recommending the use of statin
medications in the primary prevention of cardiovascular disease. The research
evaluated discovers data is inconclusive on the benefit of statin medications
in this primary prevention as well as the safety of long-term statin use. Some
experts have suggested statins are over-prescribed as it is one of the most
commonly prescribed medications in the United States. Statin medications
continue to be extremely beneficial in the secondary prevention of
cardiovascular events, but caution should be applied by providers when
prescribing this medication to their patients for primary prevention when
referring to conflicting population based guidelines. Providers should identify
key risk factors and have conversations with their patients on the risks and
benefits of statin medications when they are being utilized for the primary
prevention of cardiovascular disease.

Introduction
• Atherosclerotic plaques form in the blood vessels from particles of
cholesterol. These plaques are a major cause of cardiovascular disease
(CVD) and have the ability to result in fatal cardiovascular events (Baron,
2017).
• Data is inconclusive and differ among many studies whether the use of
statins is beneficial in primary prevention when evaluating the rate of CV
events, CVD mortality and all-cause mortality.
• HMG-CoA reductase is an enzyme involved in the first step in the
formation of cholesterol in the liver. By inhibiting HMG-CoA (the
mechanism of statin medications), the synthesis of cholesterol is reduced,
thereby reducing the levels of cholesterol found in the blood (Malloy &
Kane, 2015). With less cholesterol in the blood, atherosclerotic plaques
are not as easily formed.
• Conflicting recommendation statements can make it difficult for providers
to know which patients fall into a statin therapy benefit group. Some
patients may fall into a statin therapy benefit group with one organization,
but not another (Pagidaipati, 2017).
• Population-based recommendations have been criticized as it may seem
almost all patients can fall into one of the treatment groups. The use of
statins in the prevention of cardiovascular events is difficult to quantify as
we still do not know the exact cause of plaque formation or migration of
plaques resulting in cardiovascular events. There is also lack of information
on whether statin medications have deleterious long-term effects as the
widespread use of statins has been somewhat recent in terms of medical
research as statins were first approved for use in 1987 (Baron, 2017).

Statement of the Problem
Statin medications have become a mainstay in the primary prevention of CVD.
Controversy exists on whether cardiovascular events are truly being
prevented by the use of statins or if these medications are being overprescribed.

Research Question
In patients without existing cardiovascular disease, does taking a statin
medication (rather than not taking a statin medication) prevent
cardiovascular events?
In patients taking statins, does the benefit of taking statins outweigh the risk
of long-term statin use in the primary prevention of cardiovascular disease?

Literature Review

Recommendation Guidelines

Applicability to Clinical Practice

• DeFilippis, Young, and Blaha (2015) evaluated the AHA/ACC ASCVD risk
score with 4 other risk scores calculators to compare their efficacy. In the
4,227 patients evaluated, the researchers discovered 4 out of the 5 risk
stratification tools overestimated risk in men by 37% to 154% and 46% to
67% in 3 out of the 5 tools in women. ASCVD events were better predicted
in women than in men.

United States Preventative Task Force

• Providers can use this information to make decisions together with their
patients on whether a statin prescription is appropriate.

• Pagidaipati (2017) evaluated 3,416 subjects aged 40 to 75 years without
prior CVD. In this population, 21.5% of the subjects were taking statin
medications and an additional 15.8% of the subjects would be eligible
based on the USPSTF guidelines compared to an additional 24.3% when
looking at the ACC/AHA guidelines. Much of the discrepancy is due to the
ACC/AHA guidelines recommending statin therapy in those with diabetes
and the USPSTF guidelines do not. Others who were covered under the
ACC/AHA guidelines but not the USPSTF guidelines included younger male
smokers, younger males with dyslipidemia and younger women with
obesity.

• Diabetes, Age 40-75 and LDL 70-189 mg/dL (grade A)

• Age 40-75 and ASCVD Risk 10+% (grade B) or ASCVD Risk 7.5+% (grade C)
American College of Cardiology and American Heart Association

• Long-term use, such as greater than 15 years, of these medications, have
yet to be evaluated and is also a consideration providers should take into
account when discussing risks with their patients.

• LDL > 190 mg/dL and Age >21 (grade B)

•

– With 1+ Risk Factor (dyslipidemia, diabetes, hypertension, smoker)

• No Diabetes, Age 40-75, LDL 70-189 mg/dL, and ASCVD Risk >7.5% (grade A)
• No Diabetes, Age 40-75, LDL 70-189 mg/dL and ASCVD Risk 5+% (grade B)

Statin Mechanism of Action
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• Colhoun et al. (2004) identified 2,838 patients with T2DM who had 1+
comorbidity including HTN, retinopathy, microalbuminuria, or currently
smoking. They observed a reduction of 36% in acute coronary events, 31%
decrease in coronary revascularization events, and 48% decrease in stroke
in those taking the atorvastatin. The researchers also found in the
atorvastatin group that a 37% reduction in major CV events (p = 0.001)
and a 48% reduction in stroke occurred.

• Collins et al. (2016) concluded in 10,000 patients taking statin
medications, the adverse effects found may be 5 cases of myopathy, 50 to
100 new cases of diabetes mellitus, and 5 to 10 hemorrhagic strokes.
• Crandall et al. (2017) assessed the incidence of diabetes in patients who
are not diabetic upon starting a statin. In 3,234 participants who were
older than 25 years of age, had a BMI greater than 24 kg/m2 and had
fasting plasma glucose levels between 95 and 125 mg/dL as well as an
impaired glucose tolerance test, 33 to 37% of subjects had started a statin
medication prior to their diabetes diagnosis over a ten-year period. The
researchers concluded that statin use may be a risk factor for developing
diabetes in patients who are at high risk. They suggested if statins are
started on a high-risk patient, that the patient is monitored closely.

• With greatest benefit seen in patients with multiple risk factors, patients
with single risk factors may have the greatest effect in the risk versus
benefit discussion when determining statin appropriateness in patient
care.

References

• Knopp, d'Emden, Smilde, and Pocock (2006) evaluated 2,410 subjects with
T2DM by assessing a primary CV end point by defining those who had a CV
death, a nonfatal MI, a nonfatal CVA, recanalization, CABG, a resuscitated
cardiac arrest and worsening or unstable angina requiring hospitalization.
10.4% of those taking atorvastatin and 10.8% of those treated by the
placebo experienced a primary end point. The relative risk reduction was
found to be 19% which was not significant (p = 0.41).

• Anderssen, Hjelstuen, Hjermann, Bjerkan, and Holme (2005) evaluated
568 drug-treated hypertensive subjects over 4 yrs. When evaluating the
effect of fluvastatin alone to the placebo, there was significantly reduced
progression in common carotid artery IMT (p = 0.0297). Fluvastatin also
significantly reduced the progression of common carotid artery IMT when
comparing the groups of fluvastatin with lifestyle intervention and those
with only lifestyle interventions (p = 0.0214).

• Side effects should be frequently discussed and risks should be assessed
regularly to determine if removing the medication would be appropriate.
• Providers must assess each patient’s benefits versus risk to determine if a
statin prescription may have an effect on the primary prevention of CVD.

• ALLHAT (2002) compared patients with existing HTN with fasting LDL
cholesterol levels of 120 to 189 mg/dL. A total of 10,355 participants were
included in the study and their treatment was evaluated for up to eight
years. The researchers concluded there was no significant difference in allcause mortality when comparing pravastatin treatment to usual care (p =
0.88).

• Yusuf et al. (2016) evaluated 12,705 participants in 228 centers in 21
countries. Who were >55 years of age if male or >65 years of age if female
with 1+ of the following CVD risk factors: elevated waist-to-hip ratio,
history of a low level of HDL-C, current or recent tobacco use, dysglycemia,
FMH of premature CAD, or mild renal dysfunction. After 7 years, a CVD
event occurred in 3.7% of the participants in the rosuvastatin group and
4.8% of the participants in the placebo group (p=0.002). This resulted in a
number needed to treat with rosuvastatin to prevent one event to be 91.

As patients are diagnosed with conditions such as diabetes at much
younger ages, long-term use of statins will become more prevalent.
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Discussion
• There are discrepancies among recommendation guidelines on the
prescription of statin medications in the primary prevention of CVD.
• The risk assessment tools do not take into consideration important factors
such as diet and exercise, family history, or other comorbidities which may
increase or decrease a patient’s risk of CVD.
• The research showed benefit in some populations, especially those with
multiple risk factors. Other populations, such as those with diabetes, did
not have a significant benefit which falls against that of the ACC/AHA
recommendation guidelines.
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